Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, et al. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018;39(12):1431-1437.

Huang J, Diaz-Meco MT, Moscat J. The macroenviromental control of cancer metabolism by p62. Cell Cycle. 2018;17(17):2110-2121.

Correction: Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. Cancer Prev Res (Phila). 2018;11(4):249.

Magro CM, Telang GH, Momtahen S. Unilesional Follicular Mycosis Fungoides: Report of 6 Cases and Review of the Literature. Am J Dermatopathol. 2018;40(5):329-336.

Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontan L, et al. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discov. 2018;8(12):1632-1653.

Omay SB, Chen Y-, Almeida JP, Ruiz-Treviño AS, Boockvar JA, Stieg PE, et al. Do craniopharyngioma molecular signatures correlate with clinical characteristics? J Neurosurg. 2018;128(5):1473-1478.

Ellis L, Loda M. LSD1: A single target to combat lineage plasticity in lethal prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4530-4531.

Li W, Xia S, Aronova A, Min IM, Verma A, Scognamiglio T, et al. CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules. J Surg Oncol. 2018;118(6):1042-1049.

Wang S, Liechty B, Patel S, Weber JS, Hollmann TJ, Snuderl M, et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol. 2018;138(1):183-190.

Huse HK, Miller SA, Chandrasekaran S, Hindler JA, Lawhon SD, Bemis DA, et al. Evaluation of Oxacillin and Cefoxitin Disk Diffusion and MIC Breakpoints Established by the Clinical and Laboratory Standards Institute for Detection of -Mediated Oxacillin Resistance in Staphylococcus schleiferi. J Clin Microbiol. 2018;56(2).